Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa, Japan.
Histol Histopathol. 2023 Sep;38(9):965-974. doi: 10.14670/HH-18-607. Epub 2023 Mar 15.
This paper describes the current status of studies and clinical trials on the use of mesenchymal stem cells (MSCs) and amniotic fluid stem cells (AFSCs) for complications of preterm birth (PTB), an urgent issue in the perinatal field. PTB is a serious challenge in clinical medicine that is increasing globally, and effective control of its complications is necessary for newborns' subsequent long life. Classical treatments are inadequate, and many patients have PTB complications. A growing body of evidence provided by translational medicine and others indicates that MSCs, and among them, the readily available AFSCs, may be useful in treating PTB complications. AFSCs are the only MSCs available prenatally and are known to be highly anti-inflammatory and tissue-protective and do not form tumors when transplanted. Furthermore, because they are derived from the amniotic fluid, a medical waste product, no ethical issues are involved. AFSCs are an ideal cell resource for MSC therapy in neonates. This paper targets the brain, lungs, and intestines, which are the vital organs most likely to be damaged by PTB complications. The evidence to date and future prospects with MSCs and AFSCs for these organs are described.
本文描述了间充质干细胞（MSCs）和羊水干细胞（AFSCs）用于治疗早产并发症（PTB）的研究和临床试验现状，PTB 是围产期领域的一个紧迫问题。PTB 是全球范围内日益严重的临床医学挑战，有效控制其并发症对新生儿的长期健康至关重要。经典治疗方法效果不足，许多患者存在 PTB 并发症。转化医学和其他领域提供的越来越多的证据表明，MSCs，其中包括易于获得的 AFSCs，可能对治疗 PTB 并发症有用。AFSCs 是产前唯一可用的 MSCs，具有很强的抗炎和组织保护作用，移植后不会形成肿瘤。此外，由于它们源自羊水，这是一种医疗废物，因此不存在伦理问题。AFSCs 是新生儿 MSC 治疗的理想细胞资源。本文针对大脑、肺部和肠道，这些是最有可能因 PTB 并发症而受损的重要器官。描述了迄今为止关于这些器官的 MSC 和 AFSCs 的证据和未来前景。
